問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Rheumatology

Division of Dermatology

更新時間：2023-09-19

張雲亭Chang, Yun-Ting
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

Recruiting Trial

53Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張雲亭

List

80Cases

2020-12-31 - 2023-12-31

Phase III

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)

  • Condition/Disease

    Active Psoriatic Arthritis

  • Test Drug

    Tildrakizumab

Participate Sites
9Sites

Recruiting9Sites

2021-09-01 - 2023-07-31

Phase II

Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects with Prurigo Nodularis

  • Condition/Disease

    Prurigo Nodularis/Pruritis

  • Test Drug

    KPL-716/ vixarelimab

Participate Sites
4Sites

Recruiting4Sites

2023-01-19 - 2026-01-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-07-31 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2023-01-27 - 2025-09-30

Phase III

A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

  • Condition/Disease

    Atopic Dermatitis

  • Test Drug

    Rocatinlimab (AMG 451)

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting2Sites

Terminated1Sites

2023-02-06 - 2025-09-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2022-10-13 - 2027-04-20

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2016-09-30 - 2018-12-31

Phase III

A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer′s Disease Dementia (The DAYBREAK Study)

  • Condition/Disease

    Mild Alzheimer′s Disease

  • Test Drug

    LY3314814

Participate Sites
10Sites

Terminated10Sites

黃錦章
Linkou Chang Gung Medical Foundation

Division of Neurology

2019-07-01 - 2021-02-05

Phase II

A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO

  • Condition/Disease

    Active Non-segmental Vitiligo

  • Test Drug

    PF-06651600 and PF-06700841

Participate Sites
5Sites

Terminated5Sites

2018-12-31 - 2020-12-31

Phase II

A Randomized, Double-Blind, Placebo-Controlled Trial of AC-701 For Treatment of Skin Rash in Subjects with EGFR Inhibitor Therapy

  • Condition/Disease

    Skin Rash in Subjects with EGFR Inhibitor Therapy

  • Test Drug

    AC-701(Berberine) Gel:0.3%

Participate Sites
2Sites

Recruiting2Sites

1 4 5 6 7 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB